Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles

Journal of the American Academy of Dermatology
Neil SwansonSharon F Levy

Abstract

The approved imiquimod 5% cream regimen for treating actinic keratoses requires a long treatment time and is limited to a small area of skin. We sought to evaluate imiquimod 2.5% and 3.75% for short-course treatment of the full face or balding scalp. In two identical studies, adults with 5 to 20 lesions were randomized to placebo, imiquimod 2.5%, or imiquimod 3.75% (1:1:1). Up to two packets (250 mg each) were applied per dose once daily for two 2-week treatment cycles, with a 2-week, no-treatment interval between cycles. Efficacy was assessed at 8 weeks posttreatment. A total of 479 patients were randomized to placebo, or imiquimod 2.5% or 3.75%. Complete and partial clearance (> or =75% lesion reduction) rates were 6.3% and 22.6% for placebo, 30.6% and 48.1% for imiquimod 2.5%, and 35.6% and 59.4% for imiquimod 3.75%, respectively (P < .001 vs placebo, each; P = .047, 3.75% vs 2.5% for partial clearance). Median reductions from baseline in lesion counts were 25.0% for placebo, 71.8% for imiquimod 2.5%, and 81.8% for imiquimod 3.75% (P < .001, each active vs placebo; P = .048 3.75% vs 2.5%). There were few treatment-related discontinuations. Patient rest period rates were 0% for placebo, 6.9% for imiquimod 2.5%, and 10.6% for ...Continue Reading

References

Dec 1, 1986·The British Journal of Dermatology·R MarksT S Selwood
Jan 1, 1995·Journal of the American Academy of Dermatology·L A DrakeM L Turner
Nov 26, 1999·Journal of the American Academy of Dermatology·K R BeutnerM L Owens
Sep 17, 2003·Archives of Dermatology·A Bernard Ackerman
Dec 11, 2007·The British Journal of Dermatology·M VatveG Gupta

❮ Previous
Next ❯

Citations

May 4, 2013·American Journal of Clinical Dermatology·Aman Samrao, Clay J Cockerell
Mar 16, 2012·The New England Journal of Medicine·Mark LebwohlBrian Berman
Feb 22, 2012·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Jason HadleyMichael Hadley
Jun 22, 2011·Clinical, Cosmetic and Investigational Dermatology·Caroline Caperton, Brian Berman
Sep 8, 2012·Clinical, Cosmetic and Investigational Dermatology·Brian Berman
Jan 1, 2010·Clinical, Cosmetic and Investigational Dermatology·Joshua M Berlin
Jan 25, 2013·Clinical Interventions in Aging·Elizabeth E Uhlenhake
Mar 14, 2014·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·T Strunk, R-M Szeimies
Mar 15, 2014·Dermatology and Therapy·Annabel DoddsStephen Shumack
Nov 19, 2013·Expert Review of Anticancer Therapy·Giuseppe MicaliMaria Rita Nasca
Jul 31, 2010·Expert Opinion on Emerging Drugs·Martina UlrichEggert Stockfleth
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Sven R Quist, Harald P Gollnick
Dec 5, 2012·Expert Opinion on Investigational Drugs·Thomas MeyerEggert Stockfleth
May 17, 2014·Journal of the American Academy of Dermatology·Giuseppe MicaliRobert A Schwartz
Dec 19, 2012·Journal of the American Academy of Dermatology·Roger I Ceilley, Joseph L Jorizzo
Dec 19, 2012·Journal of the American Academy of Dermatology·George Martin, Neil Swanson
Oct 30, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·K PerisA Alomar
Mar 23, 2011·Dermatologic Clinics·Edward M Galiczynski, Allison T Vidimos
Mar 26, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Woan-Ruoh LeeJia-You Fang
Aug 31, 2012·The Journal of Investigative Dermatology·Erin Harberts, Anthony A Gaspari
Mar 10, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·L SchmitzT Dirschka
Aug 22, 2013·International Journal of Dermatology·John E Wolf, Darrell S Rigel
Dec 4, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·E Stockfleth
Dec 20, 2011·Actas dermo-sifiliográficas·C Serra-GuillénC Guillén
Aug 19, 2015·CA: a Cancer Journal for Clinicians·Karen Colbert MaressoErnest T Hawk
Aug 19, 2015·Current Problems in Cancer·Lauren MetterleNishit S Patel
Dec 4, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·G Gupta
Sep 2, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·G GuptaT Dirschka
Aug 15, 2012·Expert Opinion on Pharmacotherapy·Brian Berman, Sadegh Amini
May 27, 2015·Advances in Therapy·Erkki J SoiniKari Saarinen
Nov 20, 2012·Oncoimmunology·Erika VacchelliGuido Kroemer
Feb 19, 2015·Therapeutic Delivery·Anthony P RaphaelTarl W Prow
May 11, 2016·The Journal of Dermatological Treatment·Peter FoleyMark Lebwohl
Aug 26, 2015·Journal of the European Academy of Dermatology and Venereology : JEADV·T DirschkaE Stockfleth
Sep 21, 2016·Dermatology and Therapy·Rolf-Markus SzeimiesRobert Bissonnette
Jan 18, 2017·The British Journal of Dermatology·D de BerkerB R Hughes
Nov 1, 2016·The Journal of Dermatological Treatment·Thomas DirschkaGiovanni Pellacani
May 16, 2013·Journal of Cutaneous Medicine and Surgery·Aditya K Gupta, Maryse Paquet

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.